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Antigen-specific B cells (ASC) 1 can be isolated from other lymphoid cells by 
their ability to specifically bind antigen. ASC were shown to bind to antigen- 
coated glass bead columns by the inability of the passed cells to respond to that 
antigen  (1,  2).  Since  attempts  to  elute  the  cells with  excess  antigen were 
unsuccessful  (2), other means of obtaining the  ASC  were developed.  Three 
different approaches have been used:  (a)  adsorption to  an  insoluble  antigen 
matrix and eluting the cells by either mechanical disruption (3) or dissolution of 
the matrix (4-7), (b) adsorption to an anti-hapten affinity absorbent and eluting 
with excess hapten (8, 9), and (c) separation electronically  with the fluorescence 
activated cell sorter (10, 11). 
In the present study, ASC were obtained by another approach which does not 
directly remove ASC from other lymphoid cells as outlined above, but rather 
indirectly provides ASC  through removal of the nonantigen-specific B cells. 
Advantage  was  taken  of the  observation  that  B  cells,  upon  binding  large 
amounts of antigen, eventually lose their surface immunoglobulin (Ig), becom- 
ing relatively ~'nude"  (12). It  was  postulated that  such nude  ASC  could be 
separated from the  remaining B  cells bearing  surface Ig by rosetting with 
erythrocytes (RBC) conjugated with anti-mouse Ig (13). In fact, treating spleen 
cells with specific antigen followed by removal of  the Ig-bearing cells resulted in 
retention of B cells specific for that antigen, while over 90% of the other B cells 
were removed. Since lymphoid cells other than the B cells remained with the 
ASC, such antigen-specific B-cell-enriched spleen cell populations responded to 
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the  antigen  without  the  addition  of other  cells.  This  indirect  procedure  of 
enriching ASC is described and compared to cell  separation procedures which 
remove ASC directly. 
Materials and Methods 
Animals  and Immunization.  Male  A/J mice (The Jackson Laboratory,  Bar Harbor,  Maine) 
were immunized at 7-12 wk of age intraperitoneally (i.p.) with 100 ~g alum-precipitated turkey 
gamma globulin (TGG) in complete Freund's adjuvant. Or, mice were immunized either i.p. with 
0.2  ml  of a  10%  suspension  of burro  RBC  (BRBC)  or  intravenously  with  0.2  ml  of a  0.01% 
suspension of sheep RBC (SRBC) to prime T cells (14). TGG- and BRBC-primed animals were used 
after 5 or more wk; SRBC-primed animals were used after 6-10 days. 
Antigens.  TGG  was  isolated from  serum  of turkeys  (Burley Farms,  San  Diego,  Calif.)  by 
sodium  sulfate fractionation  (15),  followed by chromatography on Sephadex  G-200  (Pharmacia 
Fine Chemicals,  Inc.,  Piscataway,  N.  J.)  equilibrated with borate buffer containing 30  ~g/ml 
gentamicin (Schering Corp., Port Reading, N. J.). Protein collected in the 150,000 mol wt area was 
alum precipitated (16) for use as the antigen. For in vitro experiments, after column separation 
TGG was adsorbed at 4°C with A/J RBC, thymus, and spleen cells until free of mouse hemaggluti- 
nating activity, sterilized by filtration (0.22  #m Millipore detergent-free filter; Millipore Corp., 
Bedford, Mass.), and stored at -20°C at a  concentration of 2-3 mg/ml. 
BRBC (burro no. 1; Burley Farms) or SRBC (sheep no. 446; Colorado Serum Co., Denver, Colo.) 
were used either intact,  after washing three times in phosphate-buffered saline  (PBS) (0.15 M 
NaC1 and 0.001 M sodium phosphate buffer, pH 7.2), or were solubilized. Soluble RBC (RBC-Sol) 
antigens were prepared by lysing 0.2 ml of a  washed RBC pellet with 15 ml of sterile, distilled 
water. After pipetting up and down several times, the membranes were pelleted by centrifuging at 
2,000 g  for 10 min, the supernate aspirated, and the membranes resuspended in distilled water. 
After  centrifuging  again,  the  pellet  was  resuspended  in  1  ml  of sterile  PBS  with  5%  heat- 
inactivated fetal calf serum (FCS) (Grand Island Biological Co., Grand Island, N. Y.) (PBS-S) and 
sonicated  in  an  ice-water  bath  with  a  Model  W140  sonifier  (Heat  Systems-Ultrasonics,  Inc., 
Plainview,  N.  Y.)  giving three 30 s  pulses with the probe powered at 20 W.  The sonicate was 
centrifuged at 2,000 g for 10 min and the upper 3/4 removed for use. RBC-Sol were freshly prepared 
for each experiment. 
Spleen Cell Cultures.  A modified Mishell-Dutton culture system was employed for the genera- 
tion of antibody-producing cells (17). Single ceil spleen preparations were established in microtiter 
plates (no. 3040; Falcon Plastics, Div. ofBioQuest, Oxnard, Calif.). To each well was added 5 ×  105 
spleen cells in 0.3 ml minimum essential medium for suspension culture (Microbiological Associ- 
ates,  Bethesda,  Md.) containing 7.5% FCS  (lot no.  A846523; GIBCO),  sodium pyruvate (1 mM), 
nonessential amino acids (1 mM), glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 ~g/ 
ml), gentamicin (30 ~g/ml), and Hepes (5 mM) (Calbiochem, La Jolla, Calif.) and mercaptoethanol 
(4 x  10 -5 M). The cultures were not fed or rocked during the incubation period. Spleen cells were 
cultured either without antigen or with intact RBC (3  ×  105 per well) or with TGG added to the 
cultures indirectly by prebinding the TGG (18,  19).  This was done by incubating 5  ×  107 spleen 
cells with 100 ~tg TGG in 1 ml for 30-60 min at 4°C and washing three times.  After 5-6 days of 
culture,  cells from triplicate wells were pooled and assayed by a  modification of the hemolytic 
plaque technique (20).  TGG was coupled to indicator BRBC by incubating a  10%  suspension of 
BRBC  with  a  dilution of turkey  antiserum  to  BRBC  optimal  for  plaque-forming  cell  (PFC) 
detection.  After 30 min at 37°C,  the TGG-coupled BRBC were washed four times in saline. The 
turkey  antiserum  was  depleted  of IgM  by  prior  chromatography  on Sephadex  G-200.  In  this 
experimental system PFC to BRBC were always negligible in the response to TGG and direct PFC 
to  TGG  were  not  generated  (21).  The  indirect PFC  were  developed  using  rabbit  anti-mouse 
immunoglobulin facilitating serum. Results are expressed as the mean PFC per 107 original cells 
of duplicate pools with the standard error. 
Antiserum  to Mouse-Ig and  its Coupling  to RBC.  F(ab')2 fragments of goat Ig  anti-mouse 
F(ab')2 were prepared by pepsin digestion of purified antibodies eluted from an F(ab')2 mouse IgG- 
Sepharose 4B immunoadsorbent column (22).  The antiserum precipitated all classes of mouse Ig 
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1 mg of F(ab')~ fragments in 0.5 ml PBS was added to 0.1 ml gluteraldehyde-fixed (23), packed 
SRBC in 5 ml of 0.1 M sodium-acetate buffer, pH 5.0, and the mixture rotated overnight at room 
temperature. The cells were then washed six times with PBS and stored at 4°C in PBS with 0.1% 
sodium azide. The reagent is stable for several months when prepared sterilely. 
Removal of Ig-bearing Cells.  Ig-bearing cells were removed by a modification of the method of 
Parish et al. (13). Spleen cells were freed of RBC and dead cells by centrifugation through Ficoll- 
Isopaque (24). The interface cells were washed twice in PBS-S and cultured in medium with 7.5% 
FCS for 1.5 h at 37°C at 2 x 107 cells/ml to attempt to elute nonspecifically  bound Ig. The cells were 
then washed again, cooled to 4°C, and 1 x 109 anti-mouse Ig-coated RBC (anti-Ig-RBC) added to 5 
x 107 lymphocytes in 1 ml balanced salt solution with 5% FCS (BSS-S) (15). This mixture was then 
pelleted at 140g for 3 min at 4°C (tissue culture tube no. 3033, Falcon Plastics, Div. of BioQuest), 
left on ice for 30 min, and then gently resuspended by pipetting. Lymphoid cells which formed 
rosettes with anti-Ig-RBC were then separated from nonrosetted lymphoid cells by centrifugation 
at 2,000 g  at 20°C for 8 min on Ficoll-Isopaque (13). The rosettes pelleted to the bottom of the 
gradient, while lymphoid cells which did not rosette (non-Ig bearing) remained at the interface of 
medium and gradient. The interface cells were aspirated, washed two times with PBS-S,  and 
cultured. 
Retention of ASC.  The procedure was similar to the removal of Ig-bearing cells,  except that 
after removal of the dead cells and RBC by centrifugation through Ficoll-Isopaque, the washed 
interface cells were incubated in BSS-S for 30-60 rain at 4°C with the desired antigen. TGG (100 
~g) or soluble RBC antigen (0.8 ml) (see Materials and Methods, Antigens) was added to 1 ml of 5 
x  107 cells. The cells were then washed three times with PBS-S, resuspended in medium with 5% 
FCS,  incubated 1.5  h  at  37°C, washed,  and rosetted with anti-Ig-RBC as  outlined above for 
nonantigen-treated  cells. The interface spleen cells were washed two times and cultured. 
Results 
Enrichment of ASC by the Removal of Other Ig-Bearing Cells.  Ig-bearing 
cells are easily removed from mouse spleen cells by rosetting with RBC conju- 
gated with antiserum to mouse Ig and sedimenting the rosetted cells through a 
Ficoll-Isopaque gradient (13). The rosettes pellet, leaving non-Ig-bearing  cells at 
the interface. Since it was known that B cells can be induced to lose their surface 
Ig by incubation with antigen  (12),  it was postulated that prior incubation of 
spleen cells with antigen before B-cell depletion could lead to an enrichment of B 
cells specific for the antigen used in incubation upon subsequent removal of the 
other B cells. Since only nonantigen-specific  B cells would be removed and since 
B  cells represent about 50% of all spleen cells, the PFC response per 107 spleen 
cells  should  double  if all  of the  ASC  were  retained.  While  this  is  a  small 
enrichment relative to total spleen cell number, if all the B  cells were removed 
except the few ASC (estimated as less than 1% of the B cells), then enrichment of 
ASC relative to B-cell content should be considerable. 
To determine if ASC could be obtained in this manner,  specific antigen was 
incubated with spleen cells before the Ig-bearing cells were removed, as shown 
schematically in Fig. 1.  Spleen cells were either from mice primed earlier with 
TGG or  BRBC  to  elicit a  secondary,  indirect antibody response upon in vitro 
culture with antigen, or spleen cells were from mice given a low dose of SRBC 6- 
10 days prior, resulting in an enhanced primary, direct antibody response upon 
culture with SRBC. 2 TGG was added at 100/xg/ml of 5  ×  l0  T spleen cells; soluble 
2 Falkoff and  Kettman  (14) have  shown  that  a  low,  intravenous dose  of SRBC which  is 
subimmunogenic  for B cells, as evidenced by a lack of antibody synthesis, nevertheless primes T 
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FIG.  1.  Method to obtain antigen-specific B cells by removal of the other B cells. Encircled 
symbols represent T cells (T), macrophages (M), B cells (~, ASC (O), and anti-Ig-RBC (@). 
For additional explanation, see text. 
sonicates of RBC antigen were added at the equivalent of 101° intact RBC/ml of 5 
x  107  spleen  cells.  After  30-60  min  of incubation  at  4°C  to  saturate  the  Ig 
receptors  of ASC  specific  for  the  antigen,  excess  antigen  was  removed  by 
multiple washes. The spleen cells were then incubated 1.5 h at 37°C to permit Ig- 
bearing cells with bound antigen to lose their Ig receptors. This length of time 
was shown to be sufficient for antigen-induced loss of surface Ig (12).  Also, this 
time  period  probably  allowed  nonspecifically  bound  antigen  and  cytophilic 
antibody to dissociate. After being washed, the spleen cells were incubated with 
anti-Ig-RBC,  sedimented on Ficoll-Isopaque and the  interface cells recovered. 
The Fc end of the anti-mouse Ig was removed to avoid its binding to cells with Fc 
receptors. 
The effect on the antibody response of spleen cells incubated with and without 
specific antigen followed by B-cell removal is shown in Tables I and II. Spleen 
cells primed to TGG in response to TGG generated 6,201 PFC per 107 spleen cells 
put into  culture  (Table  I,  line  2),  but when  depleted of B  cells,  they did not 
respond to TGG (Table I,  line 3).  However, if they were incubated with TGG 
before B-cell depletion, the PFC response was not lost upon B-cell removal, but 
rather  it  was  increased  to  16,614  PFC  per  107  spleen  cells  put  into  culture, 
indicating retention of the TGG-specific B cells. This data is typical of six other 
experiments  done  with  TGG-primed  spleen  cells.  Next,  it  was  attempted  to 
retain  ASC specific for SRBC antigen.  As expected,  spleen cells depleted of B 
cells did not generate  PFC to SRBC upon culture  (Table II, line 6).  However, SHARYN  M.  WALKER,  G.  C.  MEINKE,  AND  WILLIAM  O.  WEIGLE 
TABLE  I 
Antibody Response of TGG-Primed Spleen Cells Incubated  with 
and without TGG before B-Cell Depletion 
Treatment* 
Before B deple-  B deple-  After B deple- 
tion  tion  tion 
PFC _+  SE 
None  -  None  <39 
TGG  -  None  6,201  +_ 662 
None  +  TGG  234  _+  83 
TGG  +  None  16,614 _+  2,483 
* Spleen cells primed to TGG were incubated with TGG either before or 
after  B-cell  depletion,  as  indicated.  Incubation of spleen cells with 
TGG as described in the text made further addition of TGG unneces- 
sary upon culture. After 6 days indirect PFC to TGG per 107 initial 
spleen cells placed into culture were determined. 
TABLE  II 
Antibody Response of SRBC-Primed Spleen Cells Incubated with 
and without Soluble  SRBC before B-CeU Depletion 
Treatment* 
Before B depletion  B depletion 
SRBC in 
PFC +_ SE  culture 
None  -  -  158 _+ 28 
None  -  +  4,393  _+  1,168 
SRBC-Sol  -  -  2,558 +_  361 
SRBC-Sol  -  +  4,643 _  1,085 
None  +  -  <19 
None  +  +  316  _+  296 
SRBC-Sol  +  -  3,837  _+ 668 
SRBC-Sol  +  +  546  _+  50 
* Spleen cells primed with a low dose of SRBC (2 × 105) in order to prime 
only T  cells (14) were incubated  with or without solubilized SRBC 
antigen followed by B-cell depletion, as indicated. Direct PFC per 107 
initial spleen cells in culture were assayed after 5 days. 
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prior incubation with soluble SRBC antigen followed by B-cell removal resulted 
in the generation of 3,837  PFC  (Table II, line 7),  indicating retention of B  cells 
specific for SRBC antigen. 
Tables I and II also show that preincubation with either TGG or soluble SRBC 
was  sufficient to  generate  PFC  without further  addition  of antigen.  For some 
reason, intact SRBC were on occasion inhibitory to soluble SRBC-treated spleen 
cells which had been depleted of B  cells (Table II,  line 8).  Most likely this was 
not  due  to  a  lack of macrophages  to  process  the  antigen,  since by  nonspecific 
esterase stain macrophages  were not removed upon B-cell depletion. 
Determination  of the  Enrichment  and  Purity  of ASC  Relative  to  B-Cell 
Content.  Enrichment  of ASC relative to other B  cells in the spleen cell prepa- 
ration was determined by rerosetting the spleen cell preparations  with anti-Ig- 
RBC  and  quantitating  the  number  of rosettes  to  determine  B-cell  content. 
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TABLE  III 
Quantitation  of B-Cell Content in TGG-Primed  Spleen Cell Cultures Enriched and 
Nonenriched  for TGG-Specific B Cells 
Treatment* 
No+ of B  Fold 
Exp.  Before B  After B  cells/100  PFC/107 cells  PFC/10~ APC/105  enrich- 
no.  deple-  B deple-  deple-  lymphoid  ±  SE  B cells  B cells$  ment 
tion  cells  tion  tion 
1  None  -  None  63 _+ 1  61  _+ 12  -  -  - 
TGG  -  None  62  _+ 1  5,612 ± 432  90  1.4  - 
None  +  TGG  4.2 _+ 0.2  244 ±  71  -  -  - 
TGG  +  None  4.1 +_ 0.3  23,729  -+ 4,090  5,790  90.4  64 
2  TGG  -  None  46 ±  2  6,215 ±  310  130  2.1  - 
TGG  +  (2x)  None  1.5 _+ 0.03§  25,816  _+ 3,203  17,211  268.7  132 
* Spleen cells primed to TGG were depleted of B cells either with or without prior incubation with 
TGG to retain TGG-specific B cells. At 0 and 20 h of culture the number of cells which rosetted 
with  anti-Ig-RBC  was  determined.  After 6  days  indirect  PFC  per  107  original cells were 
measured. 
The number of antibody precursor cells was extrapolated from kinetic curves of the appearance 
of PFC to TGG from which it was estimated that beginning on day 3, PFC to TGG doubled every 
8 h with seven doublings. 
§ B-cell number after the first B depletion was 3.5 ± 0.5%. 
cells to permit  regeneration  of surface Ig receptors,  although  the  number  of B 
cells at either time was essentially the same.  The first experiment  in Table III 
shows  that  spleen cells primed  to  TGG  and  enriched  for TGG-specific B  cells 
contained about 4% B  cells as compared to 62% before the B  cells were removed, 
indicating a  94%  reduction in B-cell content.  Despite this high degree of B-cell 
depletion, the response to TGG was increased from 5,612 PFC to 23,729 PFC per 
107 cells. Thus,  non-B-depleted cultures in response to TGG contained about 90 
PFC  per  10  ~ B  cells,  while  B-depleted,  TGG-specific B-cell cultures  contained 
5,790 PFC per 105 B  cells. This represented a  64-fold enrichment  of ASC relative 
to B-cell content. In addition, it was found that if the B cells were depleted twice, 
rather  than  once,  B-cell  number  could  be  further  reduced.  As  shown  in  the 
second experiment  in Table III, TGG-specific B-cell-enriched cultures contained 
3.5%  B  cells  when  B  depleted  once  and  1.5%  B  cells  afLer  a  second  B-cell 
depletion.  Upon  relating  PFC  to  105  B  cells in  enriched  and  nonenriched  cul- 
tures,  the purification obtained  was  132-fold. 
The purity of TGG-specific B  cells relative to other B  cells at the beginning  of 
the culture  period was estimated  from the PFC  response.  Extrapolation  of the 
PFC  response  back seven  doublings led to an  approximation  of the number  of 
APC, since prior kinetic curves of the generation  of PFC to TGG indicated that 
beginning  on day 3,  PFC  to TGG doubled every 8  h  with seven doublings (21). 
Table  III shows  that  TGG-primed  spleen  cell cultures  contained  1.4  antibody 
precursor cells (APC) in 10  ~ B  cells, while cultures enriched for TGG-specific B 
cells contained 90 APC in 105 B  cells. Thus,  about 1 in 1,000 B  cells enriched for 
ASC were capable of generating  PFC to TGG or a  purity of 0.1%. 
Recovery ofASC.  Next, the recovery of TGG-specific B  cells was determined 
to  assess  the  efficiency of the  purification method.  It was  expected,  as  stated SHARYN  M.  WALKER,  G.  C.  MEINKE,  AND  WILLIAM  O.  WEIGLE 
TABLE  IV 
Recovery of TGG-Specific B Cells from the Ficoll-Isopaque Gradient 
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Treatment* 
Before B de-  B deple- 
pletion  tion 
Cell recov-  Actual PFC/10' cells  Expected PFC!  Recovery 
cry  107 cells$  of ASC§ 
%  % 
TGG  -  100  5,612  ±  432  -  - 
TGG  +  20  23,729  +- 4,090  28,068  85 
* Spleen cells  primed  to  TGG  were treated  with  TGG  followed by  depletion  of the  B  cells  as 
indicated.  After 6 days indirect PFC per 107 original cells were measured. 
$ Expected  PFC/10 T cells  =  (PFC/107  cellsAsc-enr~ched)  X  [(%  cell  recovery  ....  ^sc-~nriche~)/(% cell 
recovery  ASC-enric  hed)]  - 
§ % Recovery ofASC =  [(Actual PFC/107 cellsAsc-~nrich~d)/(Expected  PFC/107 cellsAsc-~.riched)] ×  100. 
earlier, that if all the ASC were retained and the other B cells removed, the PFC 
response per 107 spleen cells should double. However, this is only correct if after 
gradient separation 50% of the cells were recovered at the interface. Table IV 
shows that the recovery was 20%, which indicates more than a loss of B cells. A 
20% cell recovery was typical of most experiments. As a consequence, if all the 
ASC  were  retained at the  interface, the  PFC  response  should be  increased 
fivefold, since the ASC are in 1/5 the number of  cells as compared to the original 
cell population. In fact, Table IV shows that the PFC response was increased 
from  5,612  PFC  to  23,729  PFC,  or  almost  fivefold.  Since  28,068  PFC  were 
expected if all the ASC were retained,  85%  of the TGG-specific B  cells were 
recovered.  Six other experiments with TGG  averaged 82%  recovery  (54-94% 
range). The recovery of RBC-specific B cells averaged 19% for four experiments. 
For example, Table II which shows an increase in PFC to SRBC from 2,558 PFC 
to 3,837 PFC after B-cell removal represents a 30% recovery of SRBC-specific B 
cells.  Thus, preincubation with specific antigen proved especially effective in 
preventing the depletion of TGG-specific B cells upon B-cell removal, but was 
less effective with SRBC-specific B cells. 
Requirement of Specific Antigen for Retention  of ASC.  Spleen cells were 
incubated with either the antigen used in priming or with an unrelated antigen 
to determine if specific antigen was required to retain specific B cells. Table V 
shows that treatment of SRBC-primed spleen cells with TGG did not prevent the 
removal of precursors of SRBC PFC upon B-cell depletion. On the contrary, the 
response to SRBC,  5,800  PFC, was reduced to 519  PFC, or greater than 90%. 
Similarly, the second experiment in Table V shows that incubation of BRBC- 
primed  spleen  cells  with  TGG  followed by  B-cell  depletion  did  not  prevent 
removal of the precursors to BRBC antibody-producing cells.  However, if the 
spleen  cells  were  first  incubated  with  solubilized  BRBC  antigen,  the  PFC 
response was significantly  retained, giving 3,669 PFC before B-cell removal and 
2,949 PFC after B-cell removal. 
Retention of ASC in Spleen Cells Primed to Two Different Antigens.  While 
having shown that specific antigen was required to retain ASC,  it was  still 
possible  that  significant numbers  of B  cells  capable  of responding to  other 
antigens were retained with the ASC. For this reason, spleen cells primed to two 452  ENRICHMENT  OF  ANTIGEN-SPECIFIC  B  LYMPHOCYTES 
TABLE  V 
Separation of TGG-Specific B  Cells and SRBC-Specific B  Cells from Spleen Cells 
Primed to Both TGG and SRBC 
Treatment*  PFC  ±  SE 
SRBC in 
Before B  deple-  B  deple-  After B  deple-  culture 
vs. TGG  vs.  SRBC 
tion  tion  tion 
None  -  None  -  266  ±  224  82  ±  0 
None  -  None  +  512  ±  348  1,306  ±  489 
TGG  -  None  -  14,443  ±  6,284  - 
None  +  TGG  -  82  _+  0  <41 
None  +  TGG  +  <41  <41 
TGG  +  None  -  67,650  ±  2,050  <41 
TGG  +  None  +  69,700  ±  4,100  <41 
SRBC-Sol  +  TGG  -  1,653  _+  143  959  ±  102 
SRBC-Sol  +  TGG  +  1,411  ±  466  1,187  ±  371 
* Spleen cells primed to both TGG and a low dose of SRBC to prime T cells only (14) were incubated 
either with or  without TGG  or  soluble SRBC  antigen followed by  removal of the  B  cells as 
indicated. After 6 days in culture, indirect PFC to TGG and direct PFC to SRBC per 107 initial 
spleen cells were assayed. 
different antigens were depleted of B cells before and after incubation with one 
of the priming antigens and the PFC response to both antigens assessed. Table 
VI shows that spleen cells primed to SRBC and TGG, when incubated with TGG 
followed by B-cell depletion did not generate PFC to SRBC, but did generate 
PFC to TGG (Table VI,  line 7).  On the other hand, when B  cells specific for 
SRBC antigen were retained, the response to TGG was reduced by 90%  (Table 
VI, line 9). 
Discussion 
ASC  were  separated  from B  cells  with  specificities for  other  antigens by 
modification of a simple procedure used to remove B cells from other lymphoid 
cells (13). This was accomplished by incubating mouse spleen cells with specific 
antigen before the B cells were removed by rosetting with anti-Ig-RBC. ASC 
were not removed, presumably because prior incubation with antigen caused 
the loss of their surface Ig (12). However, it is possible that not all of the Ig was 
removed, but that antigen "hid" the Ig receptor. 
ASC for TGG were enriched about 100-fold relative to B-cell content, which is 
comparable to other purification procedures. For example, ASC purified by the 
fluorescence activated cell sorter were enriched 20- to 500-fold depending on the 
antigen (11), ASC separated on an antigen-gelatin matrix were enriched 100- to 
900-fold  (6,  7, 25), and ASC eluted from an anti-hapten affinity absorbent were 
enriched 55-fold  (8) and 600-fold  (9). 
Purity of the B-depleted, TGG-specific B cells relative to B-cell content was 
estimated at about 0.1%, which is far lower than other methods estimating a 15- 
55% purity (7-9, 11, 26). However, this difference may be partially explained by 
the fact that the latter figures are routinely based on antigen-binding studies, 
while TGG-specific B-cell content was based on APC content, estimated indi- 
rectly from the number of PFC,  as  has  been  done by others  (27-29).  In our SHARYN  M.  WALKER,  G.  C.  MEINKE,  AND  WILLIAM  O.  WEIGLE  453 
TABLE  VI 
Antibody Response of  RBC-Primed Spleen Cells Incubated with and without TGG before 
B-Cell Depletion 
Treatment 
Cell source  RBC in cul-  PFC  ±  SE 
Before B  deple-  B  deple-  ture 
tion  tion 
SRBC-primed spleen*  SRBC  vs.  SRBC 
None  -  -  338  -+ 62 
None  -  +  4,238  +_  938 
TGG  -  +  5,800  ±  281 
TGG  +  +  519  +_  281 
BRBC-primed spleens  BRBC  vs. BRBC 
None  -  -  144  _+  21 
None  -  +  7,137  _+  1,629 
TGG  +  -  102  _+  21 
TGG  +  +  451  _+  62 
BRBC-Sol  -  -  3,669  +-  868 
BRBC-Sol  +  -  2,949  _+  711 
* Spleen cells from mice primed with a  low dose of SRBC to prime T cells only (14) were incubated 
with TGG followed by B-cell depletion as indicated. After 5 days of culture direct PFC per 107 
spleen cells put into culture were determined. 
$ Spleen cells from mice primed to BRBC 4 mo prior were incubated either with TGG or soluble 
BRBC antigen followed by B-cell depletion as indicated. After 6 days of culture, indirect PFC per 
107 spleen cells put into culture were determined. The few direct PFC  were subtracted. 
experiments, TGG-primed spleen cells were estimated to contain about one APC 
in 100,000 B cells or 0.001% ASC, which means that a 100-fold enrichment leads 
only to 0.1% purity. However, it is not unusual for antigen-binding studies to 
show that 0.1-2% of unpurified spleen cell preparations bind an antigen, such as 
dinitrophenyl (DNP)  (30, 31), 4-hydroxy-3-iodo-5-nitro-phenylacetyl (NIP) con- 
jugate (26), human gamma globulin (11, 32), and keyhole limpet hemocyanin 
(KLH) (8,  11) which means that a  100-fold enrichment of ASC would lead to a 
10-100%  purity in terms of antigen-binding cells. Thus, despite equal enrich- 
ment factors, since the initial number of ASC to TGG is small, the resultant 
purity is less than if the initial number of ASC were higher. 
Antigen-binding cells were not measured in this study since their number 
appears to inaccurately reflect the number of cells which can respond to antigen. 
For example, it seems unlikely that 1%, or even 0.1% of the spleen, or 1 in 500 B 
cells is  specific for one antigen if B  cells are unipotential. Estimates for the 
number of B cells capable of responding to an antigen have ranged from 1 in 
10,000 to 1 in 1,000,000 (29). In fact, it has been shown that with certain antigens 
as high as 90%  of the cells which bind antigen are not capable of producing 
antibody to that antigen (33, 34). Also, Nossal and co-workers showed that NIP- 
specific B cells could be obtained at greater than 30% purity in terms of antigen- 
binding cells  (26), while purity was 2%  as  assessed by cloning analysis (25). 
Thus, antigen-binding cell studies may overestimate the number of "functional" 
ASC, such that in actuality the purity could be considerably less than claimed. 
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generation may be underestimated for two reasons. First, the number of PFC 
does not take into account TGG-specific B cells which proliferated into memory 
cells, instead of into antibody-producing cells, and the plaque assay itself may 
not detect antibody-producing cells beyond a  certain antibody affinity. Thus, 
since estimations of absolute purity determined either by antigen binding or 
functionally by PFC generation may be subject to considerable error, it seems 
that the only valid means of evaluating various purification methods is in terms 
of the fold-purification, which does not depend on knowing the absolute purity of 
ASC, but rather the relative ASC content before and after purification. 
In the present study, B cells specific for TGG were recovered by more than 
80%, while the recovery of RBC-specific B cells was much less. This was most 
likely due to the antigen and not the method, since the RBC-Sol antigen may not 
have contained all the RBC antigens in high enough concentration to saturate 
the Ig receptors. That ASC specific to RBC were retained at all was surprising 
since the RBC-Sol preparation was so crude. Experiments are in progress with 
more purified antigens, such as trinitrophenyl (TNP)-KLH, to determine if B 
cells specific for other antigens can be recovered as efficiently as those specific 
for TGG.  In addition, the initial number of B  cells specific for TNP  may be 
higher than for TGG, leading to a higher purity of ASC upon separation. 
The procedure is highly antigen specific in that B cells primed to one antigen 
can be separated from B cells primed to another antigen. While other purifica- 
tion procedures have shown that ASC can be obtained and that they respond to 
antigen, the response of the purified ASC to  other antigens was usually not 
measured (9,  11). However, Nossal and Pike (25) have shown by generation of 
PFC  that  B  cells  enriched  for  NIP  antigen  do  not  contain  cells  capable  of 
responding to  DNP  antigen.  It is  important to  measure the  response to two 
different antigens, since only a few nonantigen-specific B cells could lead to a 
significant contamination of the very small number of functional ASC obtained. 
Advantages of the indirect purification procedure are the simplicity of obtain- 
ing the ASC and their ability to respond to antigen without addition of other 
cells. ASC can be obtained now as routinely as B cells have been removed in the 
past, and since the ASC are obtained indirectly by removal of the other B cells, 
sufficient numbers of T cells and macrophages remain to permit a  response to 
antigen. This contrasts with direct purification procedures which obtain ASC so 
depleted of others cells that in order to get an antibody response, filler cells must 
be added (25, 35). Or, if the ASC are specific for a T-dependent antigen, helper T 
cells must be added (9,  11). Thus, this latter population is pure largely in the 
sense that nonantigen-specific B  cells have been removed, which is precisely 
what the indirect procedure accomplishes, but more rapidly.  However, if one 
desires to study the effects of various T-cell subpopulations on the ASC, T cells 
in the ASC can be removed by anti-T-cell serum and complement and T cells 
added. Thus, this indirect selection procedure of ASC should be as applicable as 
methods currently employing the direct purification of ASC. 
Summary 
Antigen-specific B  cells  (ASC)  were  purified from  other  B  cells  by  prior 
incubation with specific antigen followed by rosetting with erythrocytes conju- SHARYN  M.  WALKER,  G.  C.  MEINKE,  AND  WILLIAM  O.  WEIGLE  455 
gated with  anti-mouse Ig and sedimenting  on Ficoll-Isopaque.  This procedure 
allowed the removal of most of the B  cells, while those specific for the antigen 
used  in  incubation  were  retained.  Relative  to  the  B-cell  content,  ASC  were 
enriched 64- to 132-fold.  The method is highly specific in that B  cells primed to 
two different antigens, turkey gamma globulin and sheep erythrocytes, could be 
separated from each other.  The advantages of this  indirect purification  proce- 
dure over purification procedures which obtain ASC directly are the simplicity 
of obtaining the ASC and the ability of the ASC of respond to antigen without 
the addition of other cells. 
Received for publication 24 February 1977. 
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